Antengene (FRA:722) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


FRA:722 Antengene Corp Ltd FRA:722
39 GF Score
Price €0.36
GF Value €0.16
! 5 Warning Signs
View Full Analysis

What is Antengene Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Antengene's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:722 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Antengene's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antengene Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Antengene's Margin of Safety % (DCF Earnings Based) falls into.


FRA:722
39GF Score
Antengene Corp Ltd FRA:722
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Antengene (FRA:722) Overvalued in 2026?

Based on GuruFocus' analysis, Antengene stock appears to be overvalued. The current stock price of €0.36 is trading 126.3% above its estimated GF Value™ of €0.16.

Key valuation signals for FRA:722:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.16 vs. price of €0.36 (126.3% above fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the FRA:722 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antengene Business Description

Other Exchanges 06996:Hong Kong
Address 1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
39GF Score

Get the complete analysis for FRA:722

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.36
Price
€0.16
GF Value